Invasive Aspergillosis Therapeutics Global Market Report 2025
상품코드:1826943
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
침습성 아스페르길루스증 치료제 시장 규모는 최근 꾸준히 성장하고 있습니다. 2024년 10억 8,000만 달러에서 2025년에는 11억 3,000만 달러에 달하고, CAGR 4.7%를 나타낼 전망입니다. 성과기간의 성장은 면역 결핍 상태의 발생률의 상승, 원내 진균 감염증 증가, 진단률의 상승, 아졸 내성의 출현, 헬스케어 지출 증가에 기인하는 것으로 예측됩니다.
침습성 아스페르길루스증 치료제 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 4.7%를 나타내 13억 6,000만 달러로 성장할 전망입니다. 예측기간의 성장은 만성질환의 유병률 증가, 신흥국의 헬스케어 인프라의 성장, 면역억제제의 사용 증가, 의료 종사자의 의식 증가, 지방시장에의 진단약의 확대 등에 기인하고 있습니다. 예측 기간의 주요 동향으로는 병용 요법으로의 이동, 진균 백신의 개발, 단일클론 항체 요법의 채용, 치료 프로토콜에 대한 원격 의료 통합, 치료 유전체학의 통합 등이 있습니다.
침습성 아스페르길루스증 치료제는 주로 면역결핍 환자를 앓고 있는 중증 아스페르길루스 감염을 관리하기 위한 치료법을 포함합니다. 이러한 치료에는 보리코나졸, 암포테리신 B, 에키노칸딘 등의 항진균제가 포함되며, 진균의 증식을 표적으로 하고 감염의 확대를 방지함으로써 효과를 발휘합니다. 난치성의 경우에는 면역조절제 및 수술적 개입과 같은 보조요법도 고려됩니다.
침습성 아스페르길루스증 치료제의 주요 약물 클래스별로는 아졸계, 에키노칸딘계, 폴리엔계 등이 있습니다. 항진균제의 일종인 아졸계 항진균제는 곰팡이 세포막의 중요한 성분인 에르고스테롤의 합성을 억제함으로써 기능하며, 감염증의 치료에 일반적으로 사용되고 있습니다. 이러한 치료제는 경구제와 정맥주사제 모두가 있으며, 병원 약국, 소매 약국, 온라인 약국, 전문 약국 등 다양한 채널을 통해 유통되고 있습니다.
2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 의료 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.
이 조사 보고서는 침습성 아스페르길루스증 치료제 업계 세계 시장 규모, 지역 점유율, 침습성 아스페르길루스증 치료제 시장 점유율을 가진 경쟁업체, 상세한 침습성 아스페르길루스증 치료제 시장 부문, 시장 동향, 비즈니스 기회 등 침습성 아스페르길루스증 치료제 시장 통계를 제공하는 The Business Research Company 이 침습성 아스페르길루스증 치료제 시장 조사 보고서는 업계의 현재 및 미래 시나리오를 자세히 분석하고 필요한 모든 것을 완벽한 관점에서 제공합니다.
향후 5년간의 성장률 4.7%라고 하는 예측은 전회 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과로 인해 스위스나 인도에서 수입되는 보리코나졸이나 이사브코나졸계 항진균제에 대한 접근이 제한되어 면역 결핍 환자의 결과가 손상되거나 감염증 치료비가 증가할 수 있어 큰 과제가 될 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
곰팡이 감염의 유병률 증가는 앞으로 수년간 침습성 아스페르길루스증 치료제 시장 성장을 이끌 것으로 예측됩니다. 곰팡이 감염은 조직에 침입한 곰팡이에 의해 발생하며, 일반적으로 피부, 손톱, 내장을 침범합니다. 진균 감염의 유병률 증가는 면역결핍 인구 증가, 기후 변화, 항균제 내성, 세계 여행 노출 등의 요인으로 인한 것입니다. 침습성 아스페르길루스증 치료제는 트리아졸계, 에키노칸딘계, 폴리엔계 등의 항진균제를 포함하며, 진균의 증식을 억제하고, 질병의 진행을 지연시키고, 생존율을 향상시키는 데 도움이 됩니다. 조기 진단은 유사한 발병 기전을 가진 침습성 진균 감염을 관리하는 데 매우 중요합니다. 예를 들어, 2024년 1월, 감염증 조사·정책 센터는 2023년에는 655만명 이상이 침습성 진균 감염증을 앓았고, 375만명 이상이 사망해, 이러한 질병에 직접 기인하는 사망자는 255만명으로, 지금까지의 추정을 크게 웃도는 것으로 보고했습니다. 그 결과, 곰팡이 감염의 발생률 증가는 침습성 아스페르길루스증 치료제 시장 성장을 가속하고 있습니다.
침습성 아스페르길루스증 치료제 시장 주요 기업은 접근성 향상, 비용 절감, 환자 결과 개선을 위해 제네릭 의약품을 포함한 비용 효과적인 치료를 중시하고 있습니다. 제네릭 의약품은 활성 성분, 용법, 용량, 안전성, 강도, 투여 경로, 품질, 효능은 선발 의약품과 동일하지만 일반적으로 가격이 저렴합니다. 예를 들어 2023년 9월 인도 제약회사인 BDR 파머슈티칼은 침습성 아스페르길루스증과 무코르미코시스 치료제로서 혁신적인 제네릭 의약품 디사벨 캡슐을 출시했습니다. 디사벨은 이사코나졸계 아졸계 항진균제로 이러한 심각한 진균 감염에 중요한 치료 옵션을 제공합니다. 복용량은 100mg이며 두 질병의 첫 번째 선택 약물로 자리 잡고 있습니다. 7 캡슐로 7,992 루피와 현재 혁신적인 치료제의 약 1/3의 가격이며 환자에게 비용 효율적인 대체 치료제가 됩니다.
2022년 5월 일본 제약회사인 시오노 요시제약 주식회사는 「디사벨」을 발매했습니다. 일본 제약회사인 시오노 요시제약 주식회사는 F2G Ltd.와 항진균제 오로로핌의 개발·상품화로 제휴했습니다. 이 제휴는 침습성 아스페르길루스증 및 기타 희귀 곰팡이 감염 환자의 암멧 의료 요구를 충족시키고 유럽과 아시아에서 오로로핌의 가용성을 확대하기 위한 것입니다. 이 이니셔티브는 특히 기존의 치료법이 유효하지 않거나 부적절한 것으로 밝혀진 경우 면역결핍 환자에게 구명의 가능한 치료를 제공하는 것을 목표로 합니다. F2G Ltd.는 영국에 본사를 둔 바이오 의약품 회사로 침습성 아스페르길루스증(IA)을 포함한 침습성 진균 감염을 치료하는 새로운 치료법의 개발을 전문으로 하고 있습니다.
침습성 아스페르길루스증 치료제 시장은 병원·임상 치료 서비스, 진단 검사·스크리닝, 원격 의료, 원격 컨설팅 등의 서비스를 제공하는 기업이 얻는 수익으로 구성됩니다. 시장 가치에는 서비스 제공업체가 판매하거나 서비스 제공에 포함된 관련 상품의 가치가 포함됩니다. 침습성 아스페르길루스증 치료제 시장에는 항진균제, 보조요법, 지지요법, 예방요법 판매도 포함됩니다. 이 시장에서의 상품 가치는 '팩토리 게이트(factory gate)' 가치, 즉 상품의 제조자 또는 제조자가 다른 기업(다운스트림 제조자, 도매업체, 유통업체, 소매업체 포함) 또는 직접 최종 고객에게 판매한 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품 제작자에 의해 판매되는 관련 서비스도 포함됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 침습성 아스페르길루스증 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 침습성 아스페르길루스증 치료제 시장 : 성장률 분석
세계의 침습성 아스페르길루스증 치료제 시장 실적 : 규모와 성장(2019-2024년)
세계의 침습성 아스페르길루스증 치료제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 침습성 아스페르길루스증 치료제 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 침습성 아스페르길루스증 치료제 시장 : 약제 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
아졸계 항진균제
에키노칸딘계 항진균제
폴리엔계 항진균제
기타 약제 클래스
세계의 침습성 아스페르길루스증 치료제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
정맥주사
세계의 침습성 아스페르길루스증 치료제 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
전문 약국
세계의 침습성 아스페르길루스증 치료제 시장 : 아졸계 항진균제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
트리아졸계
이미다졸
세계의 침습성 아스페르길루스증 치료제 시장 : 에키노칸딘계 항진균제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
카스포펑긴
미카펑긴
아니둘라펑긴
세계의 침습성 아스페르길루스증 치료제 시장 : 폴리엔계 항진균제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
암포테리신 B
암포테리신 B의 지질 제형
세계의 침습성 아스페르길루스증 치료제 시장 : 기타 약제 클래스 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
알릴아민
피리미딘 유사체
제7장 지역별/국가별 분석
세계의 침습성 아스페르길루스증 치료제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 침습성 아스페르길루스증 치료제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
침습성 아스페르길루스증 치료제 시장 : 경쟁 구도
침습성 아스페르길루스증 치료제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
GlaxoSmithKline PLC : 개요, 제품 및 서비스, 전략 및 재무 분석
Gilead Sciences : 개요, 제품 및 서비스, 전략 및 재무 분석
Astellas Pharma Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Shionogi & Co. Ltd
Hikma Pharmaceuticals
Cipla Ltd.
Mylan Pharmaceuticals Inc.
Zambon SpA
Mayne Pharma Group Limited
Basilea Pharmaceutica International Ltd.
Pulmocide Ltd.
F2G Ltd.
TFF Pharmaceuticals Inc.
Hetero Healthcare
Eugia Pharma
SCYNEXIS Inc.
PULMATRiX Inc.
BioSpectrum India
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
침습성 아스페르길루스증 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
침습성 아스페르길루스증 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
침습성 아스페르길루스증 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Invasive aspergillosis therapeutics encompass treatments designed to manage severe Aspergillus infections, primarily affecting immunocompromised patients. These treatments include antifungal medications such as voriconazole, amphotericin B, and echinocandins, which work by targeting fungal growth and preventing the spread of infection. In refractory cases, adjunctive therapies such as immunomodulators and surgical interventions may also be considered.
The primary drug classes for invasive aspergillosis therapeutics include azoles, echinocandins, polyenes, and others. Azoles, a class of antifungal drugs, function by inhibiting the synthesis of ergosterol, a crucial component of fungal cell membranes, and are commonly used to treat infections. These therapeutics are available in both oral and intravenous forms and are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The invasive aspergillosis therapeutics market research report is one of a series of new reports from The Business Research Company that provides invasive aspergillosis therapeutics market statistics, including the invasive aspergillosis therapeutics industry global market size, regional shares, competitors with the invasive aspergillosis therapeutics market share, detailed invasive aspergillosis therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the invasive aspergillosis therapeutics industry. This invasive aspergillosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The invasive aspergillosis therapeutics market size has grown steadily in recent years. It will grow from $1.08 billion in 2024 to $1.13 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to the rise in the incidence of immunocompromised conditions, the increase in hospital-acquired fungal infections, increased diagnosis rates, the emergence of azole resistance, and the increase in healthcare spending.
The invasive aspergillosis therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.36 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to the rising prevalence of chronic diseases, growing healthcare infrastructure in emerging economies, increasing use of immunosuppressants, rising awareness among healthcare professionals, and expansion of diagnostics to rural markets. Major trends in the forecast period include a shift towards combination therapies, the development of fungal vaccines, the adoption of monoclonal antibody therapies, the integration of telemedicine in treatment protocols, and the integration of genomics in treatment.
The forecast of 4.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose significant challenges by restricting access to voriconazole and isavuconazole antifungals imported from Switzerland and India, potentially compromising immunocompromised patient outcomes and increasing infectious disease treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of fungal infections is expected to drive the growth of the invasive aspergillosis therapeutics market in the coming years. Fungal infections, caused by fungi invading tissues, commonly affect the skin, nails, and internal organs. The rising prevalence of fungal infections is attributed to factors such as a growing immunocompromised population, climate change, antimicrobial resistance, and global travel exposure. Invasive aspergillosis therapeutics involve antifungal agents such as triazoles, echinocandins, and polyenes, which help inhibit fungal growth, slow disease progression, and improve survival rates. Early diagnosis is crucial for managing invasive fungal infections with similar pathogenic mechanisms. For instance, in January 2024, the Center for Infectious Disease Research and Policy reported that over 6.55 million people were affected by invasive fungal infections in 2023, leading to more than 3.75 million deaths, with 2.55 million directly attributed to these diseases, significantly higher than previous estimates. As a result, the increasing incidence of fungal infections is fueling the growth of the invasive aspergillosis therapeutics market.
Leading companies in the invasive aspergillosis therapeutics market are emphasizing cost-effective treatments, including generic drugs, to improve accessibility, reduce costs, and enhance patient outcomes. Generic drugs contain the same active ingredients, dosage, safety, strength, administration route, quality, and efficacy as their brand-name counterparts but are generally more affordable. For instance, in September 2023, BDR Pharmaceutical, an India-based pharmaceutical company, launched its innovative generic product, Zisavel capsules, designed to treat invasive aspergillosis and mucormycosis. Zisavel, belonging to the isavuconazole class of azole antifungals, offers a crucial therapeutic option for these serious fungal infections. Available in a 100 mg dosage, the capsules are positioned as a first-line treatment for both conditions. Priced at Rs. 7,992 for a pack of seven capsules, Zisavel is approximately one-third the cost of the current innovator therapy, providing a cost-effective alternative for patients.
In May 2022, Shionogi Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, collaborated with F2G Ltd. to develop and commercialize the antifungal agent olorofim. This partnership aims to expand the availability of olorofim in Europe and Asia, addressing the unmet medical needs of patients with invasive aspergillosis and other rare mold infections. This initiative seeks to provide a potentially life-saving treatment for immunocompromised individuals, particularly when existing therapies prove ineffective or unsuitable. F2G Ltd. is a UK-based biopharmaceutical company specializing in developing new therapies to treat invasive fungal infections, including invasive aspergillosis (IA).
Major players in the invasive aspergillosis therapeutics market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline PLC, Gilead Sciences, Astellas Pharma Inc., Shionogi & Co. Ltd, Hikma Pharmaceuticals, Cipla Ltd., Mylan Pharmaceuticals Inc., Zambon SpA, Mayne Pharma Group Limited, Basilea Pharmaceutica International Ltd., Pulmocide Ltd., F2G Ltd., TFF Pharmaceuticals Inc., Hetero Healthcare, Eugia Pharma, SCYNEXIS Inc., PULMATRiX Inc., BioSpectrum India, and Biosergen AB.
North America was the largest region in the invasive aspergillosis therapeutics market in 2024. The regions covered in invasive aspergillosis therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the invasive aspergillosis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The invasive aspergillosis therapeutics market consists of revenues earned by entities by providing services such as hospital & clinical treatment services, diagnostic testing and screening, telemedicine, and remote consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The invasive aspergillosis therapeutics market also includes sales of antifungal medications, adjunctive and supportive therapies, and prophylactic therapy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Invasive Aspergillosis Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on invasive aspergillosis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for invasive aspergillosis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The invasive aspergillosis therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Azoles; Echinocandins; Polyenes; Other Drug class
2) By Route Of Administration: Oral; Intravenous
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
Subsegments:
1) By Azoles: Triazoles; Imidazoles
2) By Echinocandins: Caspofungin; Micafungin; Anidulafungin
3) By Polyenes: Amphotericin B; Lipid Formulations Of Amphotericin B
4) By Other Drug Class: Allylamines; Pyrimidine Analogs
3. Invasive Aspergillosis Therapeutics Market Trends And Strategies
4. Invasive Aspergillosis Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Invasive Aspergillosis Therapeutics Growth Analysis And Strategic Analysis Framework
5.1. Global Invasive Aspergillosis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Invasive Aspergillosis Therapeutics Market Growth Rate Analysis
5.4. Global Invasive Aspergillosis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Invasive Aspergillosis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Invasive Aspergillosis Therapeutics Total Addressable Market (TAM)
6.1. Global Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Azoles
Echinocandins
Polyenes
Other Drug class
6.2. Global Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
6.3. Global Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Pharmacies
6.4. Global Invasive Aspergillosis Therapeutics Market, Sub-Segmentation Of Azoles, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Triazoles
Imidazoles
6.5. Global Invasive Aspergillosis Therapeutics Market, Sub-Segmentation Of Echinocandins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Caspofungin
Micafungin
Anidulafungin
6.6. Global Invasive Aspergillosis Therapeutics Market, Sub-Segmentation Of Polyenes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amphotericin B
Lipid Formulations Of Amphotericin B
6.7. Global Invasive Aspergillosis Therapeutics Market, Sub-Segmentation Of Other Drug Class, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Allylamines
Pyrimidine Analogs
7. Invasive Aspergillosis Therapeutics Market Regional And Country Analysis
7.1. Global Invasive Aspergillosis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Invasive Aspergillosis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Invasive Aspergillosis Therapeutics Market
9.1. China Invasive Aspergillosis Therapeutics Market Overview
9.2. China Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Invasive Aspergillosis Therapeutics Market
10.1. India Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Invasive Aspergillosis Therapeutics Market
11.1. Japan Invasive Aspergillosis Therapeutics Market Overview
11.2. Japan Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Invasive Aspergillosis Therapeutics Market
12.1. Australia Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Invasive Aspergillosis Therapeutics Market
13.1. Indonesia Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Invasive Aspergillosis Therapeutics Market
14.1. South Korea Invasive Aspergillosis Therapeutics Market Overview
14.2. South Korea Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Invasive Aspergillosis Therapeutics Market
15.1. Western Europe Invasive Aspergillosis Therapeutics Market Overview
15.2. Western Europe Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Invasive Aspergillosis Therapeutics Market
16.1. UK Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Invasive Aspergillosis Therapeutics Market
18.1. France Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Invasive Aspergillosis Therapeutics Market
21.1. Eastern Europe Invasive Aspergillosis Therapeutics Market Overview
21.2. Eastern Europe Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Invasive Aspergillosis Therapeutics Market
22.1. Russia Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Invasive Aspergillosis Therapeutics Market
23.1. North America Invasive Aspergillosis Therapeutics Market Overview
23.2. North America Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Invasive Aspergillosis Therapeutics Market
24.1. USA Invasive Aspergillosis Therapeutics Market Overview
24.2. USA Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Invasive Aspergillosis Therapeutics Market
26.1. South America Invasive Aspergillosis Therapeutics Market Overview
26.2. South America Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Invasive Aspergillosis Therapeutics Market
27.1. Brazil Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Invasive Aspergillosis Therapeutics Market
28.1. Middle East Invasive Aspergillosis Therapeutics Market Overview
28.2. Middle East Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Invasive Aspergillosis Therapeutics Market
29.1. Africa Invasive Aspergillosis Therapeutics Market Overview
29.2. Africa Invasive Aspergillosis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Invasive Aspergillosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Invasive Aspergillosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Invasive Aspergillosis Therapeutics Market Competitive Landscape And Company Profiles
